Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida Licenses Immune Response Modifier from 3M
July 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
July 23, 2001
- Taisho, GSK to Jointly Develop Smoking Cessation Aid
July 23, 2001
- Enhancing Competitiveness of Japanese Makers Discussed: OPIR Report
July 23, 2001
- Concomitant HD, CAPD Effective for Chronic Renal Failure: Terumo Seminar
July 23, 2001
- Reports of Medical Device Malfunctions Increasing
July 23, 2001
- REGULATORY NEWS IN BRIEF
July 23, 2001
- Aventis Obtains World Rights to New Cancer Agent from Ajinomoto
July 23, 2001
- NBI's Sales Up 28% to 790 Million Euro in 2000: Prof. Krebs of Boehringer Ingelheim
July 23, 2001
- Int'l Standards of Efficacy, Safety Cross National Boundaries: Korosho Official
July 23, 2001
- Fujisawa Obtains Rights to New Immunosuppressants from Aventis
July 23, 2001
- WORLD NEWS IN BRIEF
July 23, 2001
- Total Fertility Rate Up for the First Time in 4 Years
July 23, 2001
- Sysmex Renews Marketing Agreement with Dade Behring
July 23, 2001
- Korosho to Consider Shift from Manufacturing to Marketing Approvals
July 23, 2001
- Dainippon Obtains Approval of Myocardial Infarction Test Kit
July 23, 2001
- Cost Reduction Contributes to Good Performances: President Miyatake of Dainippon
July 23, 2001
- Toshiba, Johns Hopkins to Codevelop Less Invasive Medical Technology
July 23, 2001
- CORPORATE ROUNDUP
July 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
July 23, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…